DE-117 Spectrum 5 Study
An Open-Label, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution 0.002% in Latanoprost Low/Non-Responder Subjects Diagnosed With Primary Open-Angle Glaucoma or Ocular Hypertension - Spectrum 5 Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Santen Inc Clinical Operations
- Phone Number: 415-268-9052
- Email: clinicaltrials@santen.com
Study Locations
-
-
Arizona
-
Chandler, Arizona, United States, 85225
- Arizona Eye Center
-
-
California
-
Glendale, California, United States, 91204
- Global Research Management
-
Mission Hills, California, United States, 91345
- North Valley Eye Medical Group
-
Newport Beach, California, United States, 92663
- Eye Research Foundation
-
Petaluma, California, United States, 94954
- North Bay Eye Associates
-
Rancho Cordova, California, United States, 95670
- Martel Eye Medical Group
-
-
Connecticut
-
Danbury, Connecticut, United States, 06810
- Danbury Eye Physicians & Surgeons
-
-
Florida
-
Largo, Florida, United States, 33773
- Shettle Eye Research, Inc.
-
Ormond Beach, Florida, United States, 32174
- International Eye Associates, PA
-
-
Georgia
-
Albany, Georgia, United States, 31701-2363
- Dixon Eye Care
-
Morrow, Georgia, United States, 30260
- Clayton Eye Clinical Research, LLC
-
Roswell, Georgia, United States, 30076
- Coastal Research Associates, LEC
-
-
Kansas
-
Shawnee Mission, Kansas, United States, 66204
- Heart of America Eye Care, P.A.
-
-
Missouri
-
Saint Louis, Missouri, United States, 63128
- Tekwani Vision Center
-
Washington, Missouri, United States, 63090
- Comprehensive Eye Care Ltd
-
-
New York
-
New York, New York, United States, 10017
- NYU Langone Health Department of Ophthalmology
-
Rochester, New York, United States, 14618
- Rochester Ophthalmological Group, PC
-
Wantagh, New York, United States, 14618
- South Shore Eye Center
-
-
North Carolina
-
Asheville, North Carolina, United States, 28803
- Asheville Eye Associates, PLLC
-
Charlotte, North Carolina, United States, 28204
- Mundorf Eye Center
-
High Point, North Carolina, United States, 27262
- Cornerstone Health Care
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
- Apex Eye Clinical Research, LLC
-
Cleveland, Ohio, United States, 44115
- Abrams Eye Center
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104
- The Eye Institute
-
-
Pennsylvania
-
Cranberry Township, Pennsylvania, United States, 16066-6412
- Scott & Christie and Associates PC
-
-
South Carolina
-
Mount Pleasant, South Carolina, United States, 29464
- Glaucoma Consultants and Center for Eye Research, PA
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- VRF Eye Specialty Group
-
Memphis, Tennessee, United States, 38119
- Total Eye Care PA
-
Nashville, Tennessee, United States, 37205
- Nashville Vision Associates
-
-
Texas
-
Austin, Texas, United States, 78731
- Texas Eye, PA
-
League City, Texas, United States, 77573
- Eye Clinic of Texas
-
San Antonio, Texas, United States, 78240
- Medical Center Ophthalmology Associates
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with Primary Open-Angle Glaucoma or Ocular Hypertension in one or both eyes.
- Provide signed written informed consent.
- Diagnosis of POAG or OHT in both eyes.
- Qualifying corrected visual acuity in each eye.
- Qualifying central corneal thickness in each eye.
- Qualifying Day 1 IOP measurement at 3 time-points in both eyes after latanoprost Run-in Period.
- Qualifying Anterior chamber angle.
- Qualifying IOP measurement at 3 time-points during latanoprost Run-in Period.
Exclusion Criteria:
- Patients who cannot safely discontinue use of Ocular Hypotensive Medications during Washout.
- Patients with prior exposure to DE-117.
- History of ocular surgery specifically intended to lower IOP
- Advanced glaucoma in either eye.
- Any corneal abnormality or other condition interfering with or preventing reliable Goldmann applanation tonometry.
- Any ocular surgery or ocular laser treatment within 180 days prior to Visit 1 (Screening) and throughout the study in either eye.
- Females who are pregnant, nursing, or planning a pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: DE-117 Ophthalmic Solution 0.002%
Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
|
Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Month 3.
Time Frame: Month 3
|
IOP lowering effect of DE-117 ophthalmic solution 0.002% in Latanoprost low/non-responder subjects.
Mean Diurnal Intraocular Pressure: Analysis of Change from Baseline in IOP score at Month 3 using Paired T-test on Observed Case.
Mean Diurnal IOP is defined as the average IOP of all three timepoints (8:00,12:00, 16:00) at Month 3.
|
Month 3
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Change From Baseline in Mean Diurnal IOP at Week 2, Week 6 and Month 3
Time Frame: week 2, 6 and month 3
|
The secondary efficacy endpoint evaluated percent change from baseline in mean DIOP at week 2, 6 and month 3.
|
week 2, 6 and month 3
|
|
Change From Baseline in Mean Diurnal IOP at Week 2 and Week 6
Time Frame: week 2 and 6
|
Change from baseline (Visit 4) in mean diurnal IOP at Week 2 (Visit 5) and Week 6 (Visit 6).
|
week 2 and 6
|
|
Change From Baseline in IOP at Timepoints at Week 2
Time Frame: 08:00, 12:00 and 16:00 at Week 2
|
Change in mean IOP were evaluated at each time point at all post-baseline visits.
(Change from baseline measurement at each timepoint was calculated by deducting the baseline value at corresponding timepoint from the IOP measurement).
|
08:00, 12:00 and 16:00 at Week 2
|
|
Change From Baseline in IOP at Timepoints at Week 6
Time Frame: 08:00, 12:00 and 16:00 at Week 6
|
Change in mean IOP were evaluated at each time point at all post-baseline visits.
|
08:00, 12:00 and 16:00 at Week 6
|
|
Change From Baseline in IOP at Timepoints at Month 3
Time Frame: 08:00, 12:00 and 16:00 at month 3
|
Change in mean IOP were evaluated at each time point at all post-baseline visits.
|
08:00, 12:00 and 16:00 at month 3
|
|
Intraocular Pressure: Percent Change From Baseline by Analysis Visit and Timepoint at Week 2
Time Frame: 08:00, 12:00 and 16:00 at week 2
|
Intraocular Pressure: Percent Change from Baseline by Analysis Visit and Timepoint.
|
08:00, 12:00 and 16:00 at week 2
|
|
Intraocular Pressure: Percent Change From Baseline by Analysis Visit and Timepoint at Week 6
Time Frame: 08:00, 12:00 and 16:00 at week 6
|
Intraocular Pressure: Percent Change from Baseline by Analysis Visit and Timepoint.
|
08:00, 12:00 and 16:00 at week 6
|
|
Intraocular Pressure: Percent Change From Baseline by Analysis Visit and Timepoint at Month 3
Time Frame: 08:00, 12:00 and 16:00 at month 3.
|
Intraocular Pressure: Percent Change from Baseline by Analysis Visit and Timepoint.
|
08:00, 12:00 and 16:00 at month 3.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 011711IN
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.